Dr. Hashmi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Shahrukh Hashmi is an oncologist in Rochester, MN and is affiliated with Mayo Clinic Hospital - Rochester. He received his medical degree from Baqai University, and has been in practice 17 years. He received his Master's degree from the Yale University. He specializes in hematologic oncology and is experienced in GVHD, CAR-T cells, hematologic malignancies, cancer survivorship, and hematopoietic stem cell transplantation.
Education & Training
University of RochesterFellowship, Hematology and Medical Oncology, 2009 - 2012
Griffin HospitalResidency, Internal Medicine, 2003 - 2006
Baqai Medical and Dental CollegeClass of 2000
Yale UniversityMPH, Epidemiology
Certifications & Licensure
MN State Medical License 2012 - 2025
CT State Medical License 2006 - 2009
Clinical Trials
- Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE) Start of enrollment: 2014 Aug 29
- Tocilizumab for Chronic Graft-versus-Host Disease Treatment Start of enrollment: 2016 Feb 01
- Comparing Post-Transplant Cyclophosphamide as GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients Start of enrollment: 2021 Aug 15
Publications & Presentations
PubMed
- 700 citationsSenolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.Jamie N. Justice, Anoop M. Nambiar, Tamar Tchkonia, Nathan K. LeBrasseur, Rodolfo M. Pascual
Ebiomedicine. 2019-02-01 - 40 citationsVenous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysisMohammad Faizan Zahid, M. Hassan Murad, Mark R. Litzow, William J. Hogan, Mrinal S. Patnaik
Annals of Hematology. 2016-04-22 - 682 citationsSenolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.La Tonya J. Hickson, Larissa G.P. Langhi Prata, Shane A. Bobart, Tamara K. Evans, Nino Giorgadze
Ebiomedicine. 2019-09-01
Journal Articles
- Review Vaccinating Donors for Hematopoietic Cell Transplantation: A Systematic Review and Future PerspectivesShahrukh K Hashmi, John R Wingard, ScienceDirect
- Does Matching for SNPs in the MHC Gamma Block in 10/10 HLA-Matched Unrelated Donor-Recipient Pairs Undergoing Allogeneic Stem Cell Transplant Improve Outcomes?Eapen K Jacob, Shahrukh K Hashmi, Justin D Kreuter, William J Hogan, Dennis A Gastineau, Ann M Moyer, Mark Litzow, ScienceDirect
Lectures
- A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Impact of T-Cell Dose on Gvhd Risk after Allogeneic HLA-Matched PBSC Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Risk of Cancer-Specific Death May Remain Elevated for 30 YearsMay 6th, 2022- Sheikh Shakhbout Medical City Focuses on Holistic Care This Breast Cancer Awareness MonthOctober 9th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
